- Liquied biopsy company Angle posted a deeper annual loss, owing to planned investment in its offering.

Pre-tax losses for the year through April amounted to £7.6m, compared to losses of £6.3m a year earlier.

Angle said an FDA clinical study of 400 was in progress with four leading US cancer centres, targeted for completion this year.

'With two successful ovarian cancer studies, the initiation of our FDA clinical studies and three global healthcare companies secured as partners, Angle has established world-wide recognition and potential,' chairman Garth Selvey said.

'The acquisition of downstream analysis technology complements the Parsortix system and will, in time, allow us to offer our customers a full 'sample to answer' solution.'

'We continue to invest heavily to pursue FDA clearance for the Parsortix system as the first ever FDA cleared clinical device to harvest intact circulating tumour cells for analysis from patient blood.'

'Commencement of clinical trials at four prestigious US cancer centres marks a major step forward for the business.'

At 2:50pm: [LON:AGL] Angle PLC share price was -1.5p at 52.5p

Story provided by